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Abstract
Background: We have previously described a RAF oncogene driven transgenic mouse model for non small cell lung cancer
(NSCLC). Here we examine whether tumor initiation and growth requires the stem cell self-renewal factor Bmi1.
Principal Findings: In order to evaluate Bmi1 function in NSCLC two founder lines that differ in incidence and latency of
tumor formation were compared. Ablation of Bmi1 expression in both lines had a dramatically decreased tumor growth. As
the line with shorter latency matched the life span of Bmi1 knock out mice, these mice were chosen for further study. The
absence of Bmi1 did not decrease the number of tumor initiation in these mice as only the size and not the number of
tumors decreased. Reduction in tumor growth resulted from an increase in cell death and decrease in cell cycle progression
that corresponded with up-regulation of the p16
INK4a and p19
ARF.
Significance: The data identifies Bmi1 as an important factor for expansion but not initiation of RAF driven NSCLC.
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Introduction
Lung cancer is the leading cause of cancer death in the western
world. Based on histology two different types of lung cancer, non
small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
are defined. Overall 50% of all adenocarcinomas, the most
prevalent form of NSCLC, harbor mutations in constituents of the
mitogenic signaling cascade i.e EGFR, K-Ras and B-RAF [1].
Mutations of C-RAF are also found in NSCLC, however, at a
lower frequency.
Several systems that model lung cancer in the mouse have been
reported. The strategies to establish these models have basically
followed two different paths. 1) Induction of oncogene expression
and deletion of tumor suppressor genes via adenovirus directed
expression of Cre-recombinase [2–5]. This approach mimics
occurrence of somatic mutations in adult tissues. 2) Constitutive
oncogene expression in target cells through the use of cell type
specific promoters [6,7]. The latter models may be more
appropriate for gestationally acquired mutations. While the virally
induced models show a somewhat undefined target cell spectrum
the transgenic approach has the potential of targeting all the
transformation sensitive cells that show expression from a
particular cell type specific promoter.
We previously described the generation of transgenic lines
expressing an oncogenically activated version of the C-RAF kinase
(C-RAF BXB) under the control of the human alveolar type two
(AT2) cell specific surfactant protein C (SP-C) promoter [7]. Two
founder lines, further on referred to as BXB11 and BXB23, show
lung targeted adenoma development with high penetrance, high
incidence and short latency. Tumors are phenotypically rather
stable as no nuclear atypia or metastasis was seen on a C57Bl/6
background. A cuboidal cell type predominantly forms the
adenomas. No bronchial epithelial hyperplasia continuous with
cuboidal tumors as described for oncogenic K-Ras models [4] has
been observed. The BXB23 founder line has been used extensively
in genetic studies to analyze tumor progression influencing factors
[7–12]. Although the transgene expression in principal targets all
AT2 cells only a subset of them responded to expression of the C-
RAF BXB with the formation of tumors [7]. One explanation of
this finding is that a lung progenitor compartment responds to
mitogenic cascade signaling with expansion. Alternatively shut
down of transgene expression in the majority of AT2 cells may
occur. We favour the first possibility and assume that this
progenitor compartment is Bmi1 positive and depends on
mitogenic cascade signaling for self-renewal since treatment with
a MEK inhibitor led to preferential reduction in the fraction of
Bmi1 positive tumor cells and a dramatic decrease in tumor mass
[12]. Consistent with these findings cells of the primitive endoderm
which will give rise to lung progenitor cells show dependence on
mitogenic signaling for self-renewal rather than differentiation
[13]. It has previously been shown that the polycomb group
protein Bmi1 is a crucial factor for self-renewal in adult stem cells/
tumor stem cells through the inhibition of the INK4a/ARF locus
encoding p16
Ink4a/p19
ARF ([14], reviewed in [15]). Bmi1 has also
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[16,17] and belongs to a group of factors that have been identified
as a death-from-cancer signature in human malignancies [18].
Inthisstudywesetouttoevaluate Bmi1 functioninRAFinduced
adenomaformation. Because of the restrictedlife span of Bmi1gene
ablated mice [19] we took advantage of the higher incidence and
shorter latency of the BXB11 founder line to examine the Bmi1
dependence of adenoma growth in advanced disease.
Bmi1 ablation via crossing the Bmi12/2 background into the
BXB23 and BXB11 founder line revealed that Bmi1 is not
required for tumor initiation but for expansion of initiated cells.
Materials and Methods
Ethics statement
All animal studies were approved by the Bavarian State
authorities for animal experimentation.
Animals
BXB23 and BXB11 mice were routinely bred in the C57Bl/6
background. For generation of Bmi12/2BXB23 and Bmi12/
2BXB11 mice SP-C C-RAF BXB mice were crossed with
Bmi1+/2 mice that had been propagated on a FVB/N
background. The resulting Bmi1 heterozygous compound mice
were backcrossed with FVB/N/Bmi1+/2 mice to generate
Bmi12/2 SP-C C-RAF BXB compound mice.
Reagents and antibodies
Antibodies used for immunohistochemistry/immunofluores-
cence: Pro SP-C rabbit polyclonal antibody (Chemicon interna-
tional), CC10 goat polyclonal antibody (Santa Cruz Biotechnol-
ogy), pan-Cytokeratin rabbit polyclonal antibody (DAKO), Ki-67
mouse monoclonal antibody (Novocastra), C-RAF mouse mono-
clonal antibody (Santa Cruz Biotechnology), Bmi1 mouse
monoclonal antibody (Upstate), p19
ARF rabbit polyclonal antibody
(Abcam), c-MYC rabbit polyclonal antibody (Santa Cruz
Biotechnology), p16
INK4a rabbit polyclonal antibody (Santa Cruz
Biotechnology), rabbit monoclonal phospho-p44/p42 MAPK Thr
202/Tyr204 (phospho-ERK) antibody (Cell Signaling).
Microscopy
Fluorescence microscopy was performed using an Openlab
software (Improvision, Coventry, UK) controlled DMIRBE
microscope (Leica, Wetzlar, Germany) with a 406 Leica oil
immersion objective. All images were captured and stored as
Openlab LIF files. Images were subsequently processed using
power point and Adobe Illustrator software.
Histopathology and Immunohistochemistry/
Immunofluorescence staining
Animals were sacrificed and lungs were fixed under 25 cm
water pressure with 4% PBS buffered formalin. Histology was
done on formalin-fixed, paraffin-embedded lung specimen. 6 mm-
cut sections were deparaffinized, rehydrated in graded alcohols
and haematoxylin-eosin (H&E) stained. For quantification of
tumor incidence the number of tumors within at least five different
areas (310390 mm
2) per H&E or C-RAF stained lung sections was
counted. At least four mice were analyzed for each genotype.
Tumor volume was calculated either from H&E stained or anti-C-
RAF stained tumors from whole lung sections assuming a spherical
tumor. The diameters of the tumors were measured by using a
Leica microscope. For quantification of tumor volumes at least
four animals per genotype and age were examined: 321 tumors
from BXB11, 266 tumors from Bmi12/2BXB11, 92 tumors from
BXB23 and 54 tumors from Bmi12/2BXB23 animals at the age
of two weeks were analyzed. 133 tumors from Bmi12/2BXB11,
121 tumors from BXB23 and 4 tumors from Bmi12/2BXB23
animals at the age of three months were analyzed. For the
quantification of proliferation Ki67/pro SP-C positive cells in lung
sections from mice of the indicated genotype and age were
analyzed. A total of at least 1200 pro SP-C positive cells were
counted from five randomly selected tumors and analyzed for
Ki67 co-staining. For TUNEL staining the Dead End Fluoromet-
ric TUNEL-System (Promega) was used. A total of 20 randomly
selected tumors from four mice (Bmi12/2BXB11) and 25
randomly selected tumors from five mice (BXB11) were analyzed.
325 (+/2100) DAPI positive cells per tumor were analyzed for
TUNEL positivity. For quantification of cells with phospho-ERK
nuclear staining a minimum of 14 tumors from two mice of the
indicated genotype and age were analyzed. Semi automated
morphological analysis of lung sections from WT and Bmi12/2
animals was carried out as described in [20]. For quantification of
pro SP-C/CC10 double positive cells five randomly selected
tumors per lung section from a total of 5 animals at the ages of 2
weeks to 3 months were analyzed. Settings for image capture were
chosen that allowed the detection of double positive cells at
bronchio-alveolar-duct junctions (BADJs).
Immunofluorescence stainings were carried out according to the
following basic protocol: Paraffin embedded sections were
deparaffinized and rehydrated. For microwave antigen retrieval
sections were incubated in 10 mM citrate buffer for 6–23 min.
Slides were blocked in appropriate buffer containing either 4%
goat or donkey serum, or 1% BSA (exclusively for Bmi1 staining).
Incubation with primary antibodies was carried out overnight at
4uC followed by subsequent steps as follows: For pro SP-C/Ki67
co-staining sections were incubated with donkey anti-mouse
biotinylated antibody (1:200) and donkey anti rabbit Cy5 antibody
(1:200) for 90 min at room temperature (RT) sections were
subsequently incubated with streptavidin conjugated Alexa 555
(1:200). For Bmi1 staining sections were incubated with a
biotinylated goat anti mouse antibody in blocking buffer for
90 min at RT. After three washes with PBS the sections were
incubated with ABC reagent (Vectastain Elite ABX Kit, Vector
Labs) for 30 min at RT. Subsequently sections were incubated
with Cy5 labeled anti HRP (Horseraddish peroxidase) antibody
(1:100) in blocking buffer. For p19
ARF staining sections were
incubated with biotinylated donkey anti rabbit antibody (1:200)
90 min at RT. After three washes with PBS sections were
incubated with streptavidin conjugated Alexa 555 (1:200) in PBS,
0,2% Triton X-100, 90 min at RT. For pro SP-C/CC10 co-
staining sections were incubated with donkey anti-goat Alexa 555
(1:200) and donkey anti rabbit Cy5 (1:200) antibodies in blocking
buffer for 90 min. All stainings were finally counterstained with
DAPI before mounting.
For immunohistochemical stainings sections were deparaffi-
nized and rehydrated. For antigen retrieval sections were
incubated in 10 mM citrate buffer at 90uC for 10–20 min.
Endogenous peroxidase activity was quenched with methanol or
PBS containing 3% H2O2. For c-MYC staining, sections were
blocked 60 min with PBS containing 0.2% triton X-100 and 4%
goat serum. After primary antibody incubation over night at 4uC
sections were incubated with Goat anti rabbit biotinylated
secondary antibody at a 1:200 dilution for 60 min at RT. ABC
reagent was applied (Vectastain Elite ABX Kit, Vector Labs) and
developed in diaminobenzidine (DAB). Sections were then
counterstained with haematoxylin and mounted after dehydration.
Phospho p44/p42 MAPK staining was essentially carried out as
Bmi1 in Lung Cancer
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20 (TBST) was used for washes. Sections were blocked with TBST
containing 0.2% Triton X-100 and 5% goat serum. Secondary
antibody incubation was carried out using biotinylated goat anti-
rabbit antibody in blocking buffer for 60 min. Pan-Cytokeratin
stainings were carried out as previously described [8].
Western blot analysis of whole lung extracts
For preparation of extracts freshly prepared lungs were
transferred to a tube containing 500 ml ice cold RIPA buffer
(50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1%SDS, 0.5%
deoxycholate(DOC), 1% Nonidet P40 with protease inhibitor
cocktail). Lungs were homogenized for 5 min using an ultraturax
homogenizer in cold environment. Tubes containing the lung
homogenate were spun in a cooled centrifuge at 18000 g for
30 min. After centrifugation supernatants were transferred to a
fresh tube and aliquots taken for protein determination. The
remaining extracts were mixed with 26 Laemmli loading buffer
heated to 95uC for 5 min and either stored at 220uC or resolved
by SDS-PAGE and transferred to nitrocellulose membranes. After
a one hour blocking period in PBS (0.05% Tween, 5% powdered
skim milk) blots were incubated overnight with primary antibody,
washed three times with PBS and subsequently incubated with a
peroxidase coupled secondary antibody. After three times wash in
PBS blots were developed.
RTPCR
RNA was prepared from whole lungs of two weeks old mice
using the peqGOLD Trifast RNA preparation kit (peqlab
Biotechnologie GmbH) according to the manufacturer instruc-
tions. Samples were subjected to DNAse I treatment before
preparation of cDNAs using random hexamer primers provided
by the First Strand cDNA Synthesis Kit (Fermentas).
Real-time PCR was performed monitoring SYBR green incorpo-
ration. As an internal control the RNA levels of the HPRT gene were
monitored. Real-time PCR analysis was performed in a Roto-Gene
2000 detection system (Corbet Research). Primer sequences: HPRT:
CACAGGACTAGAACACCT; GCTGGTGAAAAGGACCTCT;
p19
ARF: GCGCTCTGGCTTTCGTGAAC; CGTGTCCAGGA-
AGCCTTCCC; p16
INK4a: CGTGAGGGCACTGCTGGAAG;
ACCAGCGTGTCCAGGAAGCC; p15
INK4b: CCAGGAAGCC-
TTCCCGAGCT; GGGGGCAAGTGGAGACGGTG; Cbx7:
CGGCCCATTGGTCAGGTCTG; GACCCTCGCCTTGTCA-
TGGC.
Results
Development of NSCLC in BXB23 and BXB11 mice
Lung adenoma formation was compared between BXB23 and
BXB11 RAF transgenic founder lines. As judged from H&E
staining there was no difference in histopathology of tumors from
both lines. However, the number of tumor foci per area was
strikingly different. Quantification of tumors showed a 4–5 fold
higher incidence in lungs of BXB11 as compared to BXB23
animals (Figure 1A). The basis of this difference between the
strains may result from the higher fraction of cells showing nuclear
phospho-ERK in BXB 11 mice (Figure S1A and B). Based on the
number of tumors per section we calculated the total amount of
tumors per lung in the range of 3000 in an average BXB23 lung
and 12000–15000 tumors in an average BXB11 lung. On the
background of approximately 1–2610
6 AT2 cells within the
mouse lung [21] we conclude that in both founder lines only a very
limited number of AT2 cells serve as tumor initiating cells. This
finding is consistent with tumor initiation in a progenitor
compartment and resistance of terminally differentiated AT2 cells
to transformation although stochastic transgene shutdown cannot
be excluded. Comparison of tumor volume between founders did
not reveal significant differences (Figure 1B). Tumors in BXB11
are more frequent and therefore more rapidly fill the lung leading
to suffocation as evident from the survival curves (Figure 1C).
Bmi1 promotes tumor growth but not tumor initiation in
both the BXB11 and BXB23 mice
Based on the observation that Bmi1 is expressed in BXB11
induced tumors and the previously described role of Bmi1 in
tumor stem cell self-renewal [14,22,23] we decided to further study
the role of Bmi1 for the development of C-RAF BXB adenomas
(Figure 2A). We generated compound mice expressing the SP-C
C-RAF BXB transgene on the Bmi1 knock out background. As the
genomic deletion of Bmi1 had no effect on lung development and
structure of the adult lung (Figure S2) any alterations in tumor
growth can be attributed to Bmi1. The analysis of the Bmi12/2
SP-C C-RAF BXB mice is hampered by the short life span of these
mice that is caused by the deletion of Bmi1 [24] and rarely allowed
monitoring of tumor development for more than three months.
We therefore first analyzed the effect of Bmi1 ablation on lung
tumor initiation in the BXB11 background as the life time of these
mice matched that of Bmi1 knock out mice. In contrast to BXB23,
BXB11 lungs showed extremely large areas of the lung occupied
by tumor tissue at three months of age. Tumor growth was
strongly reduced within lungs of Bmi12/2BXB11 mice
(Figure 2B) in two ways, first there was an approximately two
fold decrease of tumor numbers between two weeks and three
months of age (Figure 2C) and second the volume of surviving
tumors decreased (Figure 2D). Similar data was obtained for
Bmi12/2BXB23 compound mice (Figure S3). Though reduced
in size the tumors in Bmi12/2BXB11 lungs showed features of
SP-C C-RAFBXB induced adenomas as judged by analysis of cell
morphology and staining with two tumor markers (pan-cytokeratin
and pro SP-C; Figure S4). Also the shut down of transgene
expression as a consequence of Bmi1 ablation can be ruled out as a
reason for reduced tumor growth since Bmi12/2BXB11 tumors
stained positive with a C-RAF antibody (Figure S4). Consistently
the level of nuclear phospho-ERK was maintained in BXB11 and
Bmi12/2BXB11 from two weeks to three months of age
demonstrating that cessation of growth is not caused by a
reduction in signaling through the mitogenic cascade (Figure S5).
In summary the ablation of Bmi1 in BXB11 mice leads to
strongly reduced tumor growth. The initial number of tumors in
BXB11 versus Bmi12/2BXB11 however, does not show a
significant reduction in Bmi12/2BXB11 lungs, indicating that
the specification of tumor initiating cells does not depend on Bmi1.
Increased cell death and reduced fraction of cells in cycle
in Bmi12/2BXB11 animals
The strongly reduced tumor growth and the loss of tumors over
time in both founder lines with abrogated Bmi1 expression is
either a consequence of a block in cell cycle progression or
increased cell death or a combination of both. Bmi1 has previously
been implicated in promoting tumor cell survival and cell cycle
progression in a tissue culture model system [25,26]. TUNEL
staining showed a significant increase in the apoptotic cell ratio in
adenomas of three months old Bmi12/2BXB11 mice (Figure 3A
and 3C). This indicates that apoptosis is a late event in Bmi12/
2BXB11 adenomas. Next we examined growth rate. We
performed Ki-67/pro SP-C co-staining on lungs prepared from
two weeks and three months old Bmi12/2BXB11 and BXB11
Bmi1 in Lung Cancer
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Bmi1 ablation. Moreover as evident from the BXB11 control at
the age of three months the rate of growth of these tumors has also
decreased suggesting either a limited replicative lifespan for
BXB11 transformed AT2 cells or other levels of growth control
(Figure 3B and 3D).
In conclusion both tumor cell survival and cell proliferation are
affected in BXB11 mice with Bmi1 deletion and can account for
the observed reduced tumor growth.
Bmi1 dependent expression of p16
INK4a and p19
ARF
Bmi1 is implicated in cdki regulation. Most prominently
p16
INK4a, p19
ARF have been shown to be negatively regulated by
Bmi1 [27]. Therefore altered p16
INK4a/p19
ARF expression levels
could account for the reduced number of surviving and cycling cells
in Bmi12/2BXB11 tumors. We first analyzed expression of
mRNA levels of p16
INK4a by semi-quantitative RTPCR in lungs of
two weeks old BXB11 and Bmi12/2BXB11 mice (Figure 4A).
Expression levels of p16
INK4a were markedly increased in Bmi12/
2BXB11 lungs. Western blot analysis of whole lung lysates
confirmed this result on the protein level (Figure S6A).
Next we analyzed the mRNA expression levels of p19
ARF.A si n
the case of p16
INK4a, p19
ARF and p15
INK4b expression levels were
up-regulated in lungs of Bmi12/2BXB11 when compared to
BXB11 (Figure 4B and 4C). In contrast to p16
INK4a that was not
altered between wild type and BXB11 mice, we found elevated
levels of p19
ARF RNA expression also in BXB11 lungs (data not
shown). Another epigenetic regulator of the INK4a locus, Cbx7
was not significantly altered in expression upon Bmi1 ablation in
BXB11 mice (Figure 4D). Immunofluorescence staining of
Bmi12/2BXB11 and BXB11 lungs showed that p19
ARF is
expressed in lung tumors of animals of both genotypes. Differences
in the subnuclear distribution of p19
ARF are, however, evident
when Bmi12/2BXB11 and BXB11 tumors are compared. While
the ablation of Bmi1 is associated with a multi focal nuclear
staining pattern of p19
ARF in almost all tumor cells it is mostly
confined to a single locus within the nuclei of tumors in the
presence of Bmi1 (Figure S7).
Figure 1. BXB11 mice differ from BXB23 mice with respect to tumor incidence and survival. A) Quantification of tumor incidence in
BXB23 and BXB11 lungs at the age of 3 weeks (n=5 animals, for details see experimental materials). B) Quantification of tumor volume between
BXB23 and BXB11. The difference between the two founders was not significant. Data presented as Box-and-Whisker plots. Boxes delineate first and
third quartile, Whiskers represent minima and maxima respectively, medians are indicated by solid line within boxes, small squares represent
experimental outliers. p-values were calculated using Student’s t-test, only p-values indicating significance (p,0,05) are shown. C) Kaplan-Meier plot
for survival of BXB11 and BXB23 mice. P-value was calculated using Logrank test.
doi:10.1371/journal.pone.0004230.g001
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PLoS ONE | www.plosone.org 4 January 2009 | Volume 4 | Issue 1 | e4230Figure 2. Lack of Bmi1 expression correlates with reduced tumor growth but not incidence in BXB11 mice. A) Paraffin embedded lung
sections from BXB11 and Bmi12/2BXB11 lungs were stained for Bmi1 (green) and DAPI (blue). Dotted white lines delineate tumors. Scale
bar=30 mm. B) H&E staining of lung sections from BXB11 and Bmi12/2BXB11 mice at the age of two weeks and three months demonstrates
Bmi1 in Lung Cancer
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ARF
positive BXB11 tumors that might be interpreted as part of a
senescence phenotype. A potential explanation for this mild effect
may be c-MYC expression that we find in BXB11 tumor cells
(Figure S6B) and that has been recently described to revert a
sensescence phenotype in B-RAF transformed melanomas [28]. In
the absence of Bmi1 however, expression of INK4a/Arf was more
pronounced even though c-MYC expression was maintained
(Figure S6B) eventually leading to cessation of proliferation. Thus
under these conditions a c-MYC rescue may no longer operate.
No evidence for bronchio-alveolar-stem cells (BASCs) in
lung tumors independent of Bmi1
We next addressed the contribution of BASC cells to SP-C C-
RAF BXB tumor formation. To this end we performed pro SP-C/
CC10 double staining and analyzed BXB11 tumors for the
presence of double positive cells. For this analysis image
acquisition settings were chosen that allowed identification of
BASCs at BADJs. As illustrated in Figure 5, no double positive
cells could be observed in tumors.
In summary this data indicates that the pool of Bmi1
independent tumor cells that presumably represents tumor
initiating cells does not represent BASCs.
Discussion
In the current study we employed two transgenic founder lines
with lung targeted expression of C-RAF BXB for the dependence
of adenoma initiation and growth on the stem cell self-renewal
factor Bmi1. We show that BXB11 has a four fold higher
incidence and shorter latency of adenomas allowing examination
of advanced disease in the absence of Bmi1. Depletion of Bmi1 in
both the BXB23 and BXB11 background led to a pronounced
decrease in tumor growth rate and an increase in cell death within
the adenomas. In contrast no significant reduction in tumor
initiating events could be observed in both founder lines, arguing
for Bmi1 being an important factor for tumor expansion rather
then initiation.
Based on the observation, that Bmi1 is expressed in the C-RAF
BXB initiated lung adenomas and that Bmi1 is a target of RAF
signaling [19] we decided to investigate adenoma formation in the
absence of Bmi1. The abrogation of Bmi1 expression in the
BXB23 and BXB11 background did not yield a significant
reduction in tumor initiation events as defined by the number of
tumors that were formed in the various genetic combinations by
two weeks of age. Analysis of lung adenoma cells in the absence or
presence of Bmi1 did not reveal differences at the morphological
and at cell marker expression level. Therefore the absence of Bmi1
did not affect the process of tumor initiation. These results are
consistent with a previously published report showing Bmi1
independent glioma initiation albeit in the absence of INK4a [29].
The absence of Bmi1 did not affect the identity of the resulting
tumor cells with respect to morphology and expression of a limited
set of markers. These results also indicate that Bmi1 is not required
for the specification of a tumor initiating cell within the lung.
Phospho-ERK levels may compensate Bmi1 loss for short term but
not long term self renewal divisions of initiated cells as we observed
significant tumor growth in Bmi12/2BXB11 showing higher
nuclear phospho-ERK followed by cessation of cell division at late
time points (three months of age) when nuclear phosphor-ERK
was still present. In the course of our studies we also did not
observe changes in lung morphology in Bmi12/2 mice indicating
that Bmi1 is not a crucial factor for proper lung development. We
found a strong up-regulation of p19
ARF, p16
INK4a and, p15
INK4b
in whole lung RNA preparations of Bmi12/2 animals as
compared to wild type littermates. The expression of p19
ARF
can not exclusively be attributed to lung infiltrating cells of the
hematopoietic system since we do see pronounced p19
ARF
expression in AT2 cells and cells lining the bronchi in Bmi12/
2 animals (data not shown). Obviously, expression of cdkis does
not impair normal lung cell function. This finding is of interest
concerning off target effects in possible future therapeutic
strategies targeting Bmi1 in lung cancer.
Cdkis encoded at the INK4a locus are implicated in inhibition
of cell cycle progression and control of cell survival [30–32]. In line
with this we do see reduced tumor cell cycle progression in
Bmi12/2BXB11 tumors and an increase in cells undergoing
apoptosis albeit with some delay. These findings are in line with
previous results published by Liu and colleagues [25] showing in
vitro a specific effect of Bmi1 on tumor cell survival.
In agreement with previous reports showing p19
ARF up-
regulation in response to oncogenic hyperproliferative signals
[33–35], expression of p19
ARF was not restricted to the Bmi12/2
background but could also be observed to a lesser extent in BXB11
adenomas. We noted that p19
ARF localized to only one to two
distinct nuclear foci within BXB11 adenomas. This distribution
could not be observed in Bmi12/2BXB11 adenomas where
p19
ARF localized throughout the nucleus in many distinct spots.
The difference in distribution could be due to different p19
ARF
expression levels within individual tumor cells. Changes in
subnuclear distribution of p19
ARF have, however, also been
observed as a consequence of DNA damage in cell culture
experiments [36]. Whether DNA damage is increased within
Bmi12/2BXB11 tumors and accumulates during the three
months observation period thus leading to delayed apoptosis
(Figure 3A and C) is currently under investigation.
The increased p19
ARF expression is potentially relevant with
respect to the observation that the relative number of cycling cells
in BXB11 tumors decreased about 50% within 2.5 months.
Intrinsic and extrinsic factors could account for this observation.
For example the C-RAF BXB adenoma cells could have a limited
replicative life span, possibly through negative feed back regulation
as shown to be the case for constitutive activation for the mitogenic
cascade [37]. Alternatively, growth inhibitory factors might
accumulate in late tumor tissues due to crowding.
Induction of NSCLC in mouse lung has also been examined by
conditional expression of mutant K-Ras [4]. In this system BASCs
have been described to be involved in lung tumor formation.
Specifically it has been reported that K-Ras amplifies BASCs at
bronchiolar alveolar duct (BAD) junctions and that these
transformed stem cells form a stream that supplies lung tumor
foci. SP-C promoter controlled expression of RAF clearly does not
expand BASCs at BAD junctions yet is very efficient in giving rise
to NSCLC. Consistently we did not observe any BASCs within
reduced tumor burdon in Bmi12/2BXB11 lungs. Scale bar=200 mm. C and D) Analysis of tumor incidence and growth within the lungs of BXB11 and
Bmi12/2BXB11 mice. Data presented as Box-and-Whiskers plots, for details of data presentation see figure legend of Figure 1 (n$4 animals per
genotype and age, for details see experimental materials). Note that tumor incidence is increased by a factor of two when compared to Figure 1A)
because of the FVB/N genetic background introduced through mating with the Bmi12/2 mice. n.d.=not determined because tumors were
confluent. p-values were calculated using Student’s t-test only p-values indicating significance are shown.
doi:10.1371/journal.pone.0004230.g002
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PLoS ONE | www.plosone.org 6 January 2009 | Volume 4 | Issue 1 | e4230Figure 3. Increased apoptosis and reduced proliferation in Bmi12/2BXB11 tumors. A) TUNEL staining of paraffin embedded lung sections
from Bmi12/2BXB11 and BXB11 mice. DNase I treated lung sections were used as positive control. Sections treated without terminal
deoxynucleotidyl transferase served as negative control. Dotted white lines delineate tumors. Genotypes and ages as indicated. Arrows indicate
apoptotic (green) cells. Scale bar=30 mm. B) Ki67 (red)/pro SP-C (green) co- immunofluorescence staining of lung sections from BXB11 and Bmi12/
2BXB11 mice. Arrows indicate cycling tumor cells. ‘‘*’’ indicates staining artifact. Scale bar=30 mm. C) Quantification of TUNEL positive cells in lung
tumors of two weeks and three months old BXB11 and Bmi12/2BXB11 mice (n=4 animals per genotype), for details see materials and methods.
Data presented as Box-and-Whiskers plot for details of data presentation see figure legend of Figure 1. D) Quantification of Ki-67/pro SP-C double
positive cells. At least five tumors from five different animals were analyzed. p-values were calculated using Student’s t-test, only p-values indicating
significance are shown.
doi:10.1371/journal.pone.0004230.g003
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BAD junctions indicating that the histogenesis of NSCLC in these
two tumor models may differ. Nevertheless both models show
dependence of tumor expansion on Bmi1 by a mechanism that
mainly involves the INK4a/Arf locus [38]. These data suggest that
tumors in both mouse models of NSCLC may depend on the same
tumor stem cell. If this were to be the case then K-Ras tumors
should be sensitive to the mitogenic cascade blocker CI-1040 that
we have previously shown to dramatically decrease tumor burden
by differential reduction of Bmi1 positive cells in foci [12].
In summary, our results and the results of others highlight the
role of Bmi1 as a crucial factor for tumor cell expansion and
therefore as an attractive target for tumor intervention.
Supporting Information
Figure S1 phospho-ERK expression in BXB23 and BXB11 lung
tumors. A) Quantification of nuclear phospho-ERK staining
shown in B). Data is presented as Box-and-Whiskers plot for
details see legend of Figure 1. B) Immunohistochemistry for
phospho-ERK. White arrows indicate nuclear phospho-ERK
staining (dark brown). Hematoxylin (blue) was used as counter
stain. Scale bar=50 mm.
Found at: doi:10.1371/journal.pone.0004230.s001 (7.36 MB TIF)
Figure S2 Bmi12/2 and WT lungs are morphologically
indistinguishable. Semi automated analysis of lung sections from
four months old WT and Bmi12/2 animals. A) Examples of
analysed sections. B) Quantification of average air content
(air[%]), septum thickness (wall[A ˆmm]), mean linear intercept
(MLI). n=2 for each genotype.
Found at: doi:10.1371/journal.pone.0004230.s002 (6.02 MB TIF)
Figure S3 Tumor growth but not incidence depends on Bmi1 in
BXB23 and Bmi12/2BXB23 mice. A) Representative H&E
stainings of lung sections from four months old BXB23 and
Bmi12/2BXB23 mice. B and C) Analysis of tumor incidence and
growth within the lungs of Bmi12/2BXB23 and BXB23 mice.
Data presented as Box-and-Whiskers plots, for details of data
presentation see figure legend of Figure 1 (n$3 animals per
genotype and age, for details see experimental materials). p-values
Figure 4. p15
INK4b, p16
INK4a, p19
ARF and Cbx7 expression in lungs of BXB11 and Bmi12/2BXB11 mice. A–D) Semi-quantitative real time
PCR analysis of total RNA from whole lungs of two weeks old mice, genotypes as indicated. BXB11 levels were set to one. Data are representative of
two independent sets of analysis. Data show standard deviations from triplicate values. p-values were calculated using Student’s t-test, only p-values
indicating significance are shown. A) Quantification of p16
INK4a expression levels B) Quantification of p19
ARF RNA expression levels. C) Quantification
of p15
INK4b expression levels. D) Quantification of Cbx7 expression levels.
doi:10.1371/journal.pone.0004230.g004
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significance are shown. Scale bar=100 mm.
Found at: doi:10.1371/journal.pone.0004230.s003 (4.16 MB TIF)
Figure S4 pan-Cytokeratin SP-C and C-RAF expression in lung
adenomas of Bmi12/2BXB11 and BXB11 mice. Representative
immunohistological/immunofluorescence stainings of lung sec-
tions from two weeks old animals. Genotypes as indicated.
Sections were stained for pan-cytokeratin (brown), pro SP-C
(red) and C-RAF (red) as described in the materials and methods
section. Pan-cytokeratin staining was counterstained with hema-
toxylin (blue), pro SP-C and C-RAF stainings were counterstained
with DAPI (blue). Scale bar=50 mm.
Found at: doi:10.1371/journal.pone.0004230.s004 (9.77 MB TIF)
Figure S5 phospho-ERK levels do not differ between early and
late lung tumors in BXB11 and Bmi12/2BXB11 mice. A)
Quantification of nuclear phospho-ERK staining shown in B).
Data is presented as Box-and-Whiskers plot for details see legend
of Figure 1. B) Immunohistochemistry for phospho-ERK. White
arrows indicate nuclear phospho-ERK staining (dark brown).
Hematoxylin (blue) was used as counter stain. Scale bar=50 mm.
Found at: doi:10.1371/journal.pone.0004230.s005 (5.55 MB TIF)
Figure S6 p16
INK4a and c-Myc expression in BXB11 and
Bmi12/2BXB11 lungs. A) Top panel: EtBr stained agarose gel
showing PCR products of Bmi1 wild type allele genotyping.
Genomic DNA was used as template. Lower panels: Western blot
analysis of whole lung extracts. Antibodies used for blotting are
indicated on the left. Positions of C-RAF and C-RAF BXB are
indicated by arrows on the right. In accordance with lower tumor
load in Bmi12/2BXB11 lungs, lower C-RAFBXB protein levels
can be detected in these lungs. Significant levels of p16
INK4a can
only be detected in extracts from Bmi12/2BXB11 lungs.
GAPDH was used as loading control. B) Immunohistological c-
Myc staining (brown) of lung sections from three months old
animals. Genotypes as indicated. Staining was counterstained with
hematoxylin (blue). Scale bar=100 mm.
Found at: doi:10.1371/journal.pone.0004230.s006 (6.99 MB TIF)
Figure S7 Differential subnuclear distribution of p19
ARF in
BXB11 versus Bmi12/2BXB11 tumors. Immunofluorescence
staining for p19
ARF (red). Lung sections of 3 weeks old Bmi12/
2BXB11 and BXB11 mice were used for analysis. Sections were
counterstained with DAPI (blue). Arrows point to individual
nuclei. Inserts represent segment magnifications of nucleus
indicated by arrow head. Scale bar=25 mm.
Found at: doi:10.1371/journal.pone.0004230.s007 (8.48 MB TIF)
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